JOEL LEWIS - 26 Jan 2023 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
President and CEO, Director
Signature
Jack W. Callicutt, by power of attorney
Issuer symbol
GALT
Transactions as of
26 Jan 2023
Transactions value $
$0
Form type
4
Filing time
30 Jan 2023, 15:36:17 UTC
Previous filing
17 Jan 2023
Next filing
31 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Stock Option (right to buy) Award $0 +70,000 $0.000000 70,000 26 Jan 2023 Common Stock 70,000 $1.11 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2 The options vest as follows: 25% on each of June 30, 2023; December 31, 2023; June 30, 2024; and December 31, 2024.